Angelica Welch

Articles

Ibrutinib, Venetoclax, and Obinutuzumab Triplet Safe, Effective as Initial CLL Therapy

March 16th 2018

Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.

Managing Cardiac AEs in HER2-Positive Breast Cancer

March 16th 2018

Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.

Expert Highlights Immunotherapy Success in GU Cancers

March 16th 2018

Ani S. Balmanoukian, MD, discusses developments in genitourinary malignancies with promising immunotherapy breakthroughs in renal cell carcinoma and urothelial carcinoma.

Expert Emphasizes Healthy Lifestyle in Prostate Cancer Care

March 15th 2018

Stephen J. Freedland, MD, shares his insight on how to counsel patients with prostate cancer on the benefits of leading a healthier life.

Brahmer Highlights Latest on Immunotherapy and Other Lung Cancer Advances

March 8th 2018

Julie R. Brahmer, MD, discusses first-line immunotherapy, targeted therapies for molecularly driven tumors, and recently released guidelines for the treatment of patients with lung cancer.

Goldberg Gives Expert Insight on EGFR-TKI Resistant NSCLC

March 7th 2018

Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.

Expert Addresses Advances and Challenges in Bladder Cancer

March 7th 2018

Mark Tyson, MD, discusses the management of localized advanced bladder cancer, the promise of immunotherapy, and his advice for urologists treating patients with bladder cancer.

Schwartzberg Highlights Existing and Emerging Targets in NSCLC

March 6th 2018

Lee Schwartzberg, MD, discusses the importance of next-generation sequencing and the state of biomarker development in the management of patients with NSCLC.

Optimal Sequencing Key to Capitalizing on RCC Advances

March 6th 2018

Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.

Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC

March 2nd 2018

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

Efforts Continue to Enhance Stem Cell Transplants

March 1st 2018

Carlos R. Bachier, MD, discusses the evolution of stem cell transplantation as a treatment for patients with hematologic malignancies.

Optimizing Immunotherapy in Lung Cancer

March 1st 2018

Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.

Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer

February 27th 2018

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

Berdeja Looks Ahead in Multiple Myeloma Treatment

February 26th 2018

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Gomella Discusses Apalutamide Approval and Other Progress in Prostate Cancer

February 23rd 2018

Leonard Gomella, MD, shares his insight on the recent FDA approvals and other ongoing progress in the treatment of patients with prostate cancer.

Gastrointestinal Cancers Entering Age of Precision Medicine

February 21st 2018

Aiwu Ruth He, MD, PhD, discusses the future of precision medicine in gastrointestinal cancers.

Immunotherapy Trials Offer Hope in Advanced Penile Cancer

February 20th 2018

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.

Combinations Continue to Push CLL Field Forward

February 19th 2018

Jacqueline C. Barrientos, MD, discusses recent combination trials in CLL, and emerging agents in the pipeline.

MCL Expert Highlights Recent Advancements in Field

February 16th 2018

Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.

Pembrolizumab Update Solidifies Survival Benefit in Bladder Cancer

February 15th 2018

Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.